Akebia Therapeutics (AKBA) Q2 FY26 earnings call

Akebia Therapeutics reported strong Vafseo growth, driven by increasing patient adoption and positive clinical trial results from the VOICE study, which demonstrated Vafseo's superiority in reducing hospitalization. While overall revenues declined due to Auryxia's generic competition, the company is advancing its rare kidney disease pipeline with ebribafusp and praliciguat, aiming to build long-term value. Engagement with major dialysis organizations like DaVita is intensifying, signaling potential for future growth.